Clinicopatholgical correlates of plasma cell CD56 (NCAM) expression in multiple myeloma

Leukemia and Lymphoma

Volumn 49, Issue 2, 2008, Pages 298-305

  Kraj, Maria ^a   Sokołowska, Urszula ^a   Kopec Szlȩzak, Joanna ^a   Pogłód, Ryszard ^a   Kruk, Barbara ^a   Wozniak, Jolanta ^a   Szpila, Tomasz ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

CD56; Multiple myeloma; NCAM; Plasma cell leukemia; Plasma cells

Indexed keywords

CARMUSTINE; CD38 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METHYLPREDNISOLONE; NERVE CELL ADHESION MOLECULE; PREDNISONE; SYNDECAN 1; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOLYSIS; PLASMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SURVIVAL RATE; CASE CONTROL STUDY; CHEMISTRY; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, PLASMA CELL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOLYSIS; PLASMA CELLS; SURVIVAL RATE;

EID: 38849106764     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701760532     Document Type: Article

References (40)

1. Cunningham, B. A., Hemperly, J. J., Murray, B. A., Prediger, E. A., Brackenbury, R. and Edelman, G. M. (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science, 236, pp. 799-806.
2. Lanier, L. L., Testi, R., Bindi, J. and Phillips, J. H. (1989) Identity of Leu-19 (CD56) leucocyte differentiation antigen and neural cell adhesion molecule. J Exp Med, 169, pp. 2233-2238.
3. Barker, H. F., Hamilton, M. S., Ball, J., Drew, M. and Franklin, I. (1992) Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol, 81, pp. 331-335.
4. Drach, J., Gattringer, C. and Huber, H. (1991) Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol, 83, pp. 418-422.
5. Pellat-Deceunynck, C., Barille, S., Puthier, D., Rapp, M. I., Harousseau, J. L., Bataille, M. and Amiot, R. (1995) Adhesion molecules on human myeloma cells: Significant changes in expression related to malignancy, tumor spreading and immortalization. Cancer Res, 55, pp. 3647-3653.
6. Pellat-Deceunynck, C., Barille, S., Jego, G., Puthier, D., Robillard, N. and Pineau, D. (1998) The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia, 12, pp. 1977-1982.
7. Van Camp, B., Durie, B GM, Spier, C., de Waele, M., van Riet, I. and Vela, E. (1990) Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood, 76, pp. 377-386.
8. Van Riet, I., de Waele, M., Remels, L., Lacor, P., Schots, R. and van Camp, B. (1991) Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol, 79, pp. 421-427.
9. Ely, S. A. and Knowles, D. M. (2002) Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol, 160, pp. 1293-1299.
10. Sahara, N., Takeshita, A., Shigeno, K., Fujisawa, S., Takeshita, K. and Naito, K. (2002) Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol, 117, pp. 882-885.
11. Sahara, N. and Takeshita, A. (2004) Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma, 45, pp. 61-65.
12. Mateo, G., Castellanos, M., Rasillo, A., Gutierrez, N. C., Montalban, M. A. and Martin, M. L. (2005) Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res, 11, pp. 3661-3663.
13. Kaiser, U., Auerbach, B. and Oldenburg, M. (1996) The neural cell adhesion molecule NCAM in multiple myeloma. Leuk Lymphoma, 20, pp. 389-395.
14. Rawstron, A. C., Barrans, S. L., Blythe, D., Davies, F., English, A. and Pratt, G. (1999) Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol, 104, pp. 138-143.
15. Chang, H., Bartlett, E. S., Paterson, B., Chen, C. I. and Yi, Q. L. (2005) The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol, 129, pp. 539-541.
16. Mori, A., Tsutsumi, Y., Hashino, S., Kanamori, H., Ibata, M. and Mashiko, S. (2005) CD56 expression is the potent prognostic marker of the thalidomide efficacy in the patients with multiple myeloma. Blood, 106, pp. 368b-369b.
17. Chang, H., Samiee, S. and Yi, Q. L. (2006) Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma, 47, pp. 43-47.
18. + is the common phenotype of myeloma cells. Ann Hematol, 64, pp. 132-139.
19. Matthew, P., Ahmann, G. J., Witzig, T. E., Roche, P. C., Kyle, R. A. and Greipp, P. R. (1995) Clinicopathological correlates of CD56 expresion in multiple myeloma: A unique entity?. Br J Haematol, 90, pp. 459-461.
20. Greipp, P. R., Miguel, J San, Durie, B GM, Crowley, J. J., Barlogie, B. and Bladé, J. (2005) International Staging System for multiple myeloma. J Clin Oncol, 23, pp. 3412-3420.
21. Miwa, H., Mizutani, M., Mahmud, N., Yamaguchi, M., Takahashi, T. and Shikami, M. (1998) Biphasic expression of CD4 in acute myelocytic leukemia (AML) cells: AML of monocyte origin and hematopoietic precursor cell origin. Leukemia, 12, pp. 443-451.
22. Davis, K. A., Abrams, B., Hoffman, R. A. and Bishop, J. E. (1996) Quantitation and valence of antibodies bound to cells. Cytometry, p. 150.
23. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R. and Howard, S. V. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer, 35, pp. 1-39.
24. Bladé, J., Samson, D., Reece, D., Apperley, J., Björkstrand, B. and Gahrton, G. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol, 102, pp. 1115-1123.
25. Kraj, M., Pogłód, R., Szpila, T. and Warzocha, K. (2007) The efficacy and safety of bortezomib in the treatment of plasma cell leukemia. Acta Haematol Polonica, 38, pp. 156-157.
26. Bataille, R., Jégo, G., Robillard, N., Barillé-Nion, S., Harousseau, J-L and Moreau, P. (2006) The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica, 91, pp. 1234-1240.
27. Lin, P., Owens, R., Tricot, G. and Wilson, C. S. (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol, 121, pp. 482-488.
28. Kraj, M., Kopec-Szlȩzak, J., Pogoł́d, R., Sokołowska, U. and Kruk, B. (2007) Homogenous and non-homogenous CD138 expression on myeloma plasma cells. Proceedings of the 13th International Congress of Immunology Rio de Janeiro, Brazil Medimond, pp. 187-192. Bologna, Italy
29. Hubschmann, M. V., Skladchikova, G., Bock, E. and Berezin, V. (2005) Neural cell adhesion molecule function is regulated by metalloproteinase - mediated ectodomain release. J Neurosci Res, 80, pp. 826-837.
30. Jarahian, M., Watzl, C., Issa, Y., Altevogt, P. and Momburg, F. (2007) Blockade of natural killer cell-mediated lysis by NCAM expressed on tumor cells. Int J Cancer, 120, pp. 2625-2634.
31. + multiple myeloma cells. Cancer Res, 64, pp. 4629-4636.
32. Chanan-Khan, A. A., Jagannath, S., Schlossman, R. L., Fram, R. J., Falzone, R. M. and Ruberti, M. F. (2006) Phase I study of BB-10901 (huN901-DM1) in patient with relapsed and relapsed/refractory CD56- positive multiple myeloma. Blood, 108
33. Nadav, L., Katz, B. Z., Baron, S., Cohen, N., Naparstek, E. and Geiger, B. (2006) The generation and regulation of functional diversity of malignant plasma cells. Cancer Res, 66, pp. 8608-8616.
34. Edvardsen, K., Chen, W., Rucklidge, G., Walsh, F. S., Obrink, B. and Bock, E. (1993) Transmembrane neural cell-adhesion molecule (NCAM), but not glycosyl-phosphatidylinositol-anchored NCAM, down-regulates secretion of matrix metalloproteinases. Proc Natl Acad Sci USA, 90, pp. 11463-11467.
35. + multiple myeloma cells. Exp Hematol, 34, pp. 736-744.
36. Hundemer, M., Klein, U., Hose, D., Raab, M. S., Cremer, F. W. and Jauch, A. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transpl
37. Dahl, I. M., Rasmussen, T., Kauric, G. and Husebekk, A. (2002) Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol, 116, pp. 273-277.
38. Schwartz, T. H., Rhiew, R., Isaacson, S. R., Orazi, A. and Bruce, J. N. (2001) Association between intracranial plasmacytoma and multiple myeloma: Clinicopathological outcome study. Neurosurgery, 49, pp. 1039-1044.
39. Kouno, T., Watanabe, T., Umeda, T., Beppu, Y., Kojima, R. and Sungwon, K. (2005) CD56 - positive small round cell tumor: Osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora. Jpn J Clin Oncol, 35, pp. 90-93.
40. Grogan, T. M., Spier, C. M., Salmon, S. E., Matzner, M., Rybski, J. and Weinstein, R. S. (1993) P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. Blood, 81, pp. 490-495.